Luminex Corporation
Austin, TX 78727
Share:
Luminex Corporation Receives CE-IVD Mark for ARIES System and ARIES HSV 1 and 2 Assay
AUSTIN, Texas - Luminex Corporation (NASDAQ: LMNX) today announced that it has received CE-IVD marking for the ARIES-® System and ARIES® HSV 1 and 2 Assay. The ARIES® System and ARIES® HSV 12 Assay previously received FDA clearance in October 2015 and were subsequently launched in the U.S. market. We are excited to have received a CE-IVD mark for the ARIES® System and ARIES® HSV...
Read More »Luminex Corporation Receives CE-IVD Mark for ARIES System and ARIES HSV 1 and 2 Assay
AUSTIN, Texas - Luminex Corporation (NASDAQ: LMNX) today announced that it has received CE-IVD marking for the ARIESÃ-® System and ARIESî HSV 1 and 2 Assay. The ARIESî System and ARIESî HSV 12 Assay previously received FDA clearance in October 2015 and were subsequently launched in the U.S. market. We are excited to have received a CE-IVD mark for the ARIESî System...
Read More »Luminex Corporation to Feature ARIES System and NxTAG Respiratory Pathogen Panel at AMP Annual Meeting
Recently cleared products will be highlighted at workshops, product demonstrations, events, and posters AUSTIN, Texas - Luminex Corporation (NASDAQ: LMNX) today announced that it will be featuring the newly FDA-cleared ARIES-® System and recently CE-marked NxTAG® Respiratory Pathogen Panel at the Association for Molecular Pathology (AMP) Annual Meeting occurring November 5 to 7, 2015 in...
Read More »Luminex Corporation to Feature ARIES System and NxTAG Respiratory Pathogen Panel at AMP Annual Meeting
Recently cleared products will be highlighted at workshops, product demonstrations, events, and posters AUSTIN, Texas - Luminex Corporation (NASDAQ: LMNX) today announced that it will be featuring the newly FDA-cleared ARIESÃ-® System and recently CE-marked NxTAGî Respiratory Pathogen Panel at the Association for Molecular Pathology (AMP) Annual Meeting occurring November 5 to 7, 2015...
Read More »Respiratory Assay simultaneously detects 22 pathogens.
With tube strip design accommodating throughput required to respond to seasonal changes in demand, NxTAG™ Respiratory Pathogen Panel (RUO) lets laboratories simultaneously detect 22 respiratory pathogens in closed tube system. Functionality minimizes required hands-on time and eliminates upstream reagent preparation requirements. Total turnaround time is ~3 hr for 96 samples (excluding...
Read More »Respiratory Assay simultaneously detects 22 pathogens.
With tube strip design accommodating throughput required to respond to seasonal changes in demand, NxTAG™ Respiratory Pathogen Panel (RUO) lets laboratories simultaneously detect 22 respiratory pathogens in closed tube system. Functionality minimizes required hands-on time and eliminates upstream reagent preparation requirements. Total turnaround time is ~3 hr for 96 samples (excluding...
Read More »Luminex Corporation Announces Group B Streptococcus (GBS), as a Launch Menu Assay for Its New Sample-to-Answer System, ARIES(TM)
AUSTIN, Texas - Luminex Corporation (NASDAQ: LMNX) today announced that Group B Streptococcus (group B strep, GBS) is the fifth assay planned for the launch menu of its new sample-to-answer system, ARIES™. The assay will complement Luminex's growing portfolio of ASR and IVD products. Previously announced items in the five assay launch menu targeted for the ARIES system include: Flu A/B and RSV,...
Read More »Luminex Corporation Announces Group B Streptococcus (GBS), as a Launch Menu Assay for Its New Sample-to-Answer System, ARIES(TM)
AUSTIN, Texas - Luminex Corporation (NASDAQ: LMNX) today announced that Group B Streptococcus (group B strep, GBS) is the fifth assay planned for the launch menu of its new sample-to-answer system, ARIES™. The assay will complement Luminex's growing portfolio of ASR and IVD products. Previously announced items in the five assay launch menu targeted for the ARIES system include: Flu A/B and RSV,...
Read More »Luminex Corporation Receives FDA and European Clearance for an Updated Version of Its Comprehensive Genotyping Assay, xTAG® CYP2D6 Kit
Luminex Submits xTAG-® CYP2C19 Kit to FDA for Review AUSTIN, Texas – Luminex Corporation (NASDAQ: LMNX) today announced it has received U.S. FDA and European clearance for a new version of xTAG CYP2D6 Kit. Additionally the company has submitted xTAG 2C19 Kit to FDA for review. Luminex is advancing its pharmacogenetic initiative for improved patient care. Test results that inform a...
Read More »Luminex Corporation Receives FDA and European Clearance for an Updated Version of Its Comprehensive Genotyping Assay, xTAG-® CYP2D6 Kit
Luminex Submits xTAGÃ-® CYP2C19 Kit to FDA for Review AUSTIN, Texas – Luminex Corporation (NASDAQ: LMNX) today announced it has received U.S. FDA and European clearance for a new version of xTAG CYP2D6 Kit.ÃÂ Additionally the company has submitted xTAG 2C19 Kit to FDA for review. Luminex is advancing its pharmacogenetic initiative for improved patient care. Test results that inform a...
Read More »Luminex Receives BARDA Award to Support 510(k) Filing for NxTAG Respiratory Pathogen Panel That Includes SARS-CoV-2
High-throughput diagnostic test will include most up-to-date respiratory pathogen targets AUSTIN, Texas, Sept. 24, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received a $5,389,813 award from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S....
Read More »Luminex Receives BARDA Award to Support 510(k) Filing for NxTAG Respiratory Pathogen Panel That Includes SARS-CoV-2
High-throughput diagnostic test will include most up-to-date respiratory pathogen targets AUSTIN, Texas, Sept. 24, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received a $5,389,813 award from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S....
Read More »Luminex Corporation Receives CE-IVD Mark for ARIES System and ARIES HSV 1 and 2 Assay
AUSTIN, Texas - Luminex Corporation (NASDAQ: LMNX) today announced that it has received CE-IVD marking for the ARIES-® System and ARIES® HSV 1 and 2 Assay. The ARIES® System and ARIES® HSV 12 Assay previously received FDA clearance in October 2015 and were subsequently launched in the U.S. market. We are excited to have received a CE-IVD mark for the ARIES® System and ARIES® HSV...
Read More »Luminex Corporation Receives CE-IVD Mark for ARIES System and ARIES HSV 1 and 2 Assay
AUSTIN, Texas - Luminex Corporation (NASDAQ: LMNX) today announced that it has received CE-IVD marking for the ARIESÃ-® System and ARIESî HSV 1 and 2 Assay. The ARIESî System and ARIESî HSV 12 Assay previously received FDA clearance in October 2015 and were subsequently launched in the U.S. market. We are excited to have received a CE-IVD mark for the ARIESî System...
Read More »Luminex Corporation to Feature ARIES System and NxTAG Respiratory Pathogen Panel at AMP Annual Meeting
Recently cleared products will be highlighted at workshops, product demonstrations, events, and posters AUSTIN, Texas - Luminex Corporation (NASDAQ: LMNX) today announced that it will be featuring the newly FDA-cleared ARIES-® System and recently CE-marked NxTAG® Respiratory Pathogen Panel at the Association for Molecular Pathology (AMP) Annual Meeting occurring November 5 to 7, 2015 in...
Read More »Luminex Corporation to Feature ARIES System and NxTAG Respiratory Pathogen Panel at AMP Annual Meeting
Recently cleared products will be highlighted at workshops, product demonstrations, events, and posters AUSTIN, Texas - Luminex Corporation (NASDAQ: LMNX) today announced that it will be featuring the newly FDA-cleared ARIESÃ-® System and recently CE-marked NxTAGî Respiratory Pathogen Panel at the Association for Molecular Pathology (AMP) Annual Meeting occurring November 5 to 7, 2015...
Read More »Respiratory Assay simultaneously detects 22 pathogens.
With tube strip design accommodating throughput required to respond to seasonal changes in demand, NxTAG™ Respiratory Pathogen Panel (RUO) lets laboratories simultaneously detect 22 respiratory pathogens in closed tube system. Functionality minimizes required hands-on time and eliminates upstream reagent preparation requirements. Total turnaround time is ~3 hr for 96 samples (excluding...
Read More »Respiratory Assay simultaneously detects 22 pathogens.
With tube strip design accommodating throughput required to respond to seasonal changes in demand, NxTAG™ Respiratory Pathogen Panel (RUO) lets laboratories simultaneously detect 22 respiratory pathogens in closed tube system. Functionality minimizes required hands-on time and eliminates upstream reagent preparation requirements. Total turnaround time is ~3 hr for 96 samples (excluding...
Read More »Luminex Corporation Announces Group B Streptococcus (GBS), as a Launch Menu Assay for Its New Sample-to-Answer System, ARIES(TM)
AUSTIN, Texas - Luminex Corporation (NASDAQ: LMNX) today announced that Group B Streptococcus (group B strep, GBS) is the fifth assay planned for the launch menu of its new sample-to-answer system, ARIES™. The assay will complement Luminex's growing portfolio of ASR and IVD products. Previously announced items in the five assay launch menu targeted for the ARIES system include: Flu A/B and RSV,...
Read More »Luminex Corporation Announces Group B Streptococcus (GBS), as a Launch Menu Assay for Its New Sample-to-Answer System, ARIES(TM)
AUSTIN, Texas - Luminex Corporation (NASDAQ: LMNX) today announced that Group B Streptococcus (group B strep, GBS) is the fifth assay planned for the launch menu of its new sample-to-answer system, ARIES™. The assay will complement Luminex's growing portfolio of ASR and IVD products. Previously announced items in the five assay launch menu targeted for the ARIES system include: Flu A/B and RSV,...
Read More »